Your browser doesn't support javascript.
loading
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof, Inger S; Casneuf, Tineke; van Velzen, Jeroen; van Kessel, Berris; Axel, Amy E; Syed, Khaja; Groen, Richard W J; van Duin, Mark; Sonneveld, Pieter; Minnema, Monique C; Zweegman, Sonja; Chiu, Christopher; Bloem, Andries C; Mutis, Tuna; Lokhorst, Henk M; Sasser, A Kate; van de Donk, Niels W C J.
Afiliación
  • Nijhof IS; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;
  • Casneuf T; Janssen Research & Development, Beerse, Belgium;
  • van Velzen J; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;
  • van Kessel B; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • Axel AE; Janssen Research & Development, Spring House, PA; and.
  • Syed K; Janssen Research & Development, Spring House, PA; and.
  • Groen RW; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • van Duin M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Minnema MC; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;
  • Zweegman S; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • Chiu C; Janssen Research & Development, Spring House, PA; and.
  • Bloem AC; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;
  • Mutis T; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • Lokhorst HM; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;
  • Sasser AK; Janssen Research & Development, Spring House, PA; and.
  • van de Donk NW; Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
Blood ; 128(7): 959-70, 2016 08 18.
Article en En | MEDLINE | ID: mdl-27307294
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / ADP-Ribosil Ciclasa 1 / Inactivadores del Complemento / Anticuerpos Monoclonales / Mieloma Múltiple Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / ADP-Ribosil Ciclasa 1 / Inactivadores del Complemento / Anticuerpos Monoclonales / Mieloma Múltiple Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article